LaunchPad Medical Wins NIH HEAL Grant to Reduce Opioid Use and Addiction

06Nov

LaunchPad Medical Wins NIH HEAL Grant to Reduce Opioid Use and Addiction

Portfolio News
LaunchPad Medical, Inc. announced that it has received a grant from the National Institutes of Health through its Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, to improve strategies for the prevention and treatment for opioid misuse and addiction.Read more >>

Share this post

Related Posts

09Nov

High-tech glasses share the gift of sight

Years ago, losing your eyesight meant a permanent condition with life-altering consequences. But as many people in Calabash found out Thursday,... read more
23May

Nixing PFAS is a Real Possibility: Here’s One Company That’s Doing It

Per- and polyfluorinated substances (PFAS) have been getting a lot of negative publicity. And with good reason. Classified as “forever... read more
14Oct

With a high-speed camera that live-streams video, goggles give visually impaired users a new look at life

Alex Curtis’ grandchildren think the thick goggles make him look like a spaceman. With the dark lenses and the cord... read more
23Aug

UMassFive Adds Student-loan Repayment Benefits as Employee Perk

UMassFive College Federal Credit Union announced it is bringing student-loan repayment benefits to its employees via a new partnership between... read more
01Oct

Electronic glasses improve sight of legally blind teen

A teen who is legally blind from Bucks County is getting help from electronic glasses that help to improve his... read more
30Sep

EcoSoul Home Launches Export Factory in Muzaffarnagar, Uttar Pradesh

New Delhi, September 29, 2023 – EcoSoul Home has opened a bagasse-based products export factory in Muzaffarnagar, Uttar Pradesh. It... read more
25Jan

Myomo Completes Repayment of Loan to the Massachusetts Life Sciences Center

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, and the Massachusetts Life Sciences... read more
03May

Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc. today announced the completion of subject enrollment in RESOLVE-1, a Phase 3 study assessing the efficacy... read more
27Jul

Cause related ads increase fourfold

Purpose-driven ads are not only growing in number, but they generate more views and drive more results in the form... read more
24Mar

The Best Canned Wine for Every Palate (Whether You’re into Red, White or Rosé)

"We’re not wine snobs here, which is why we’re fully on board with the canned wine trend. They’re portable, easy... read more